A melanoma progressziójának laboratóriumi markerei

Translated title of the contribution: Laboratory markers of melanoma progression

Bánfalvi Teodóra, Édesné B. Mariann, Gergye Mária, N. Udvarhelyi, Orosz Zsolt, K. Gilde, T. Kremmer, Ottó Szabolcs, J. Tímár

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Extracellular tumour markers may have potential role in the follow-up of patients with malignant melanoma, in therapy monitoring and in prediction of prognosis. In our article circulating tumour markers in melanoma (melanoma inhibitory activity, lipid bound sialic acid, neuron specific enolase, TA90 immunkomplex, S-100B protein, 5-S-cysteinyldopa, tyrosinase, cytokines, metalloproteinases, LDH) were reviewed. Among laboratory melanoma markers the S-100B protein is the most investigated. S-100B protein has high specificity, appropriate sensitivity and proved to be significant prognostic factor independent from stages. High serum values are associated with shorter survival. However, before S-100B monitoring immunohistochemistry for the detection of S-100B is required. In the case of malignant melanomas with low expression serum S-100B monitoring may not be sensitive enough to follow disease progression. Although the serum concentration of 5-S-cysteinyldopa did not prove to be independent prognostic factor in our previous studies comprising the highest patient number in the literature, the marker was suggested for therapy monitoring. The survival analysis indicated that the elevated 5-S-cysteinyldopa level predicts shorter survival. In spite of the calculated low correlation between the two markers, parallel elevation of S-100B protein and 5-S-cysteinyldopa indicated shorter survival. On the basis of the literature LDH is the most appropiate tumour marker in stage IV to predict prognosis, but its sensitivity and specificity could not achieve that of S-100B protein. S-100B and LDH proved to be similarly reliable in respect to the clinical outcome. Determination of serum concentration of MIA and tyrosinase are also reliable markers in malignant melanoma. The other investigated markers are not well known yet or do not provide useful information to the clinicians.

Original languageHungarian
Pages (from-to)89-104
Number of pages16
JournalMagyar Onkologia
Volume47
Issue number1
Publication statusPublished - 2003

Fingerprint

S100 Calcium Binding Protein beta Subunit
Cysteinyldopa
Melanoma
Biomarkers
Tumor Biomarkers
Monophenol Monooxygenase
Protein S
Serum
Survival
Sensitivity and Specificity
Phosphopyruvate Hydratase
Metalloproteases
N-Acetylneuraminic Acid
Survival Analysis
Disease Progression
Immunohistochemistry
Cytokines
Lipids
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Teodóra, B., Mariann, É. B., Mária, G., Udvarhelyi, N., Zsolt, O., Gilde, K., ... Tímár, J. (2003). A melanoma progressziójának laboratóriumi markerei. Magyar Onkologia, 47(1), 89-104.

A melanoma progressziójának laboratóriumi markerei. / Teodóra, Bánfalvi; Mariann, Édesné B.; Mária, Gergye; Udvarhelyi, N.; Zsolt, Orosz; Gilde, K.; Kremmer, T.; Szabolcs, Ottó; Tímár, J.

In: Magyar Onkologia, Vol. 47, No. 1, 2003, p. 89-104.

Research output: Contribution to journalArticle

Teodóra, B, Mariann, ÉB, Mária, G, Udvarhelyi, N, Zsolt, O, Gilde, K, Kremmer, T, Szabolcs, O & Tímár, J 2003, 'A melanoma progressziójának laboratóriumi markerei', Magyar Onkologia, vol. 47, no. 1, pp. 89-104.
Teodóra B, Mariann ÉB, Mária G, Udvarhelyi N, Zsolt O, Gilde K et al. A melanoma progressziójának laboratóriumi markerei. Magyar Onkologia. 2003;47(1):89-104.
Teodóra, Bánfalvi ; Mariann, Édesné B. ; Mária, Gergye ; Udvarhelyi, N. ; Zsolt, Orosz ; Gilde, K. ; Kremmer, T. ; Szabolcs, Ottó ; Tímár, J. / A melanoma progressziójának laboratóriumi markerei. In: Magyar Onkologia. 2003 ; Vol. 47, No. 1. pp. 89-104.
@article{6da6a5b8ab414c75b8a97cbe29b49134,
title = "A melanoma progresszi{\'o}j{\'a}nak laborat{\'o}riumi markerei",
abstract = "Extracellular tumour markers may have potential role in the follow-up of patients with malignant melanoma, in therapy monitoring and in prediction of prognosis. In our article circulating tumour markers in melanoma (melanoma inhibitory activity, lipid bound sialic acid, neuron specific enolase, TA90 immunkomplex, S-100B protein, 5-S-cysteinyldopa, tyrosinase, cytokines, metalloproteinases, LDH) were reviewed. Among laboratory melanoma markers the S-100B protein is the most investigated. S-100B protein has high specificity, appropriate sensitivity and proved to be significant prognostic factor independent from stages. High serum values are associated with shorter survival. However, before S-100B monitoring immunohistochemistry for the detection of S-100B is required. In the case of malignant melanomas with low expression serum S-100B monitoring may not be sensitive enough to follow disease progression. Although the serum concentration of 5-S-cysteinyldopa did not prove to be independent prognostic factor in our previous studies comprising the highest patient number in the literature, the marker was suggested for therapy monitoring. The survival analysis indicated that the elevated 5-S-cysteinyldopa level predicts shorter survival. In spite of the calculated low correlation between the two markers, parallel elevation of S-100B protein and 5-S-cysteinyldopa indicated shorter survival. On the basis of the literature LDH is the most appropiate tumour marker in stage IV to predict prognosis, but its sensitivity and specificity could not achieve that of S-100B protein. S-100B and LDH proved to be similarly reliable in respect to the clinical outcome. Determination of serum concentration of MIA and tyrosinase are also reliable markers in malignant melanoma. The other investigated markers are not well known yet or do not provide useful information to the clinicians.",
author = "B{\'a}nfalvi Teod{\'o}ra and Mariann, {{\'E}desn{\'e} B.} and Gergye M{\'a}ria and N. Udvarhelyi and Orosz Zsolt and K. Gilde and T. Kremmer and Ott{\'o} Szabolcs and J. T{\'i}m{\'a}r",
year = "2003",
language = "Hungarian",
volume = "47",
pages = "89--104",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - A melanoma progressziójának laboratóriumi markerei

AU - Teodóra, Bánfalvi

AU - Mariann, Édesné B.

AU - Mária, Gergye

AU - Udvarhelyi, N.

AU - Zsolt, Orosz

AU - Gilde, K.

AU - Kremmer, T.

AU - Szabolcs, Ottó

AU - Tímár, J.

PY - 2003

Y1 - 2003

N2 - Extracellular tumour markers may have potential role in the follow-up of patients with malignant melanoma, in therapy monitoring and in prediction of prognosis. In our article circulating tumour markers in melanoma (melanoma inhibitory activity, lipid bound sialic acid, neuron specific enolase, TA90 immunkomplex, S-100B protein, 5-S-cysteinyldopa, tyrosinase, cytokines, metalloproteinases, LDH) were reviewed. Among laboratory melanoma markers the S-100B protein is the most investigated. S-100B protein has high specificity, appropriate sensitivity and proved to be significant prognostic factor independent from stages. High serum values are associated with shorter survival. However, before S-100B monitoring immunohistochemistry for the detection of S-100B is required. In the case of malignant melanomas with low expression serum S-100B monitoring may not be sensitive enough to follow disease progression. Although the serum concentration of 5-S-cysteinyldopa did not prove to be independent prognostic factor in our previous studies comprising the highest patient number in the literature, the marker was suggested for therapy monitoring. The survival analysis indicated that the elevated 5-S-cysteinyldopa level predicts shorter survival. In spite of the calculated low correlation between the two markers, parallel elevation of S-100B protein and 5-S-cysteinyldopa indicated shorter survival. On the basis of the literature LDH is the most appropiate tumour marker in stage IV to predict prognosis, but its sensitivity and specificity could not achieve that of S-100B protein. S-100B and LDH proved to be similarly reliable in respect to the clinical outcome. Determination of serum concentration of MIA and tyrosinase are also reliable markers in malignant melanoma. The other investigated markers are not well known yet or do not provide useful information to the clinicians.

AB - Extracellular tumour markers may have potential role in the follow-up of patients with malignant melanoma, in therapy monitoring and in prediction of prognosis. In our article circulating tumour markers in melanoma (melanoma inhibitory activity, lipid bound sialic acid, neuron specific enolase, TA90 immunkomplex, S-100B protein, 5-S-cysteinyldopa, tyrosinase, cytokines, metalloproteinases, LDH) were reviewed. Among laboratory melanoma markers the S-100B protein is the most investigated. S-100B protein has high specificity, appropriate sensitivity and proved to be significant prognostic factor independent from stages. High serum values are associated with shorter survival. However, before S-100B monitoring immunohistochemistry for the detection of S-100B is required. In the case of malignant melanomas with low expression serum S-100B monitoring may not be sensitive enough to follow disease progression. Although the serum concentration of 5-S-cysteinyldopa did not prove to be independent prognostic factor in our previous studies comprising the highest patient number in the literature, the marker was suggested for therapy monitoring. The survival analysis indicated that the elevated 5-S-cysteinyldopa level predicts shorter survival. In spite of the calculated low correlation between the two markers, parallel elevation of S-100B protein and 5-S-cysteinyldopa indicated shorter survival. On the basis of the literature LDH is the most appropiate tumour marker in stage IV to predict prognosis, but its sensitivity and specificity could not achieve that of S-100B protein. S-100B and LDH proved to be similarly reliable in respect to the clinical outcome. Determination of serum concentration of MIA and tyrosinase are also reliable markers in malignant melanoma. The other investigated markers are not well known yet or do not provide useful information to the clinicians.

UR - http://www.scopus.com/inward/record.url?scp=0043203049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043203049&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 89

EP - 104

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -